CONFORMED COPY

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1933

~~May~~June 144, 2009

Pharmaxis Ltd

2/10 Rodborough Road,
Frenchs Forest, NSW 2086
Australia

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

Form 20-F þ Form 40-F o

(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)

Yes o No þ

(If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .)

ASX/NASDAQ Media Release 144 ~~May~~June 2009

~~U.S.~~Pharmaxis ~~FDA~~Announces ~~Accepts~~Placement ~~AridolTM~~of ~~New~~$47 ~~Drug~~Million ~~Application~~and ~~for~~Share ~~Review~~Purchase Plan

Pharmaxis (ASX: PXS, ~~NASDAQ~~Nasdaq: PXSL) today announced that it had ~~received~~raised ~~notification~~A$47 million ~~from~~through ~~the United~~a ~~States~~placement ~~Food~~to Australian and ~~Drug~~international ~~Administration~~institutions ~~(FDA) that~~and ~~the~~professional ~~New~~investors. ~~Drug~~The ~~Application~~placement strengthens ~~(NDA) for~~the ~~its~~company’s ~~mannitol bronchial~~balance ~~challenge~~sheet ~~test~~as ~~Aridol™~~Pharmaxis ~~has~~moves ~~been~~toward ~~accepted~~the ~~for~~European ~~standard~~and ~~review~~U.S. ~~The FDA will advise the~~commercial ~~result~~launch of ~~the~~its ~~review~~product onBronchitol 27for ~~December 2009~~cystic fibrosis.

Pharmaxis iswill ~~seeking~~issue ~~approval~~20 million ~~for~~new ~~Aridol~~fully ~~for~~paid ~~“the~~ordinary ~~assessment~~shares ofat ~~bronchial~~A$2.35 ~~hyperresponsiveness~~per ~~to aid~~share, ina ~~the~~10.6% discount ~~diagnosis~~to ofPharmaxis’ ~~patients~~last ~~with~~closing ~~symptoms~~price ofon or1 ~~suggestive~~June 2009 ofand ~~asthma~~an 8.”5% ~~Asthma~~discount ~~affects~~to ~~more than 34 million people in~~ the ~~U.S.~~volume weighted ~~with~~average anshare ~~annual~~price ~~economic~~over ~~cost~~the ofpast ~~$19.7~~30 ~~billion~~days. ~~When~~The ~~approved, Aridol~~shares ~~will~~to be ~~the~~issued ~~first~~will ~~dry~~rank ~~powder~~equally ~~bronchial~~with existing ~~challenge~~ordinary ~~test~~shares ~~available~~ in the Ucapital of the company.S.

~~Alan~~The ~~Robertson,~~placement ~~Pharmaxis~~has ~~Chief Executive Officer said: “We have~~ been ~~greatly~~managed ~~encouraged~~ by ~~the interest~~Wilson ~~respiratory~~HTM ~~physicians~~Corporate ~~have~~Finance ~~shown~~Limited inand ~~Aridol~~closed ~~at recent U~~oversubscribed.~~S. scientific conferences. We~~ ~~estimate~~Settlement ~~that~~of ~~200,000 bronchial hyper-responsiveness tests are performed in~~ the USplacement ~~each~~is ~~year~~scheduled ~~and hope that the introduction of a dry powder test kit will encourage more physicians~~ to ~~utilize~~take ~~this test~~place ~~when~~on ~~diagnosing~~10 ~~asthma~~June 2009. ~~We look forward to working with the FDA to complete the review.”~~

~~Aridol~~A isshare ~~approved~~purchase ~~for~~plan ~~sale~~will inbe ~~most~~offered ~~major~~to ~~European~~all ~~countries,~~Australian ~~Australia~~ and ~~Korea.~~New ~~Aridol~~Zealand ~~has~~shareholders ~~been~~who hold ~~included~~shares inas ~~the~~at ~~Global~~7.00pm ~~Initiative~~on ~~for~~1 ~~Asthma~~June 2009 ~~guidelines,~~ and inwill afford the ~~U.S.~~opportunity ~~Asthma~~to ~~Management Guidelines.~~purchase Itup isto ~~one~~$5,000 worth of ~~the~~fully ~~tests~~paid ~~recommended~~ordinary byshares at the ~~World~~placement ~~Anti-Doping~~price ~~Agency~~of A$2.35, ~~and~~without ~~other~~brokerage ~~sports~~or transaction ~~governing~~costs. ~~bodies~~The toshare ~~ensure~~purchase ~~elite~~plan ~~athletes~~offer ~~who~~opens ~~are~~on ~~asthmatic~~10 ~~are~~June ~~properly~~and ~~diagnosed~~closes ~~and~~on ~~treated~~24 June 2009. The share purchase plan will be capped at A$10 million.

“The proceeds from this offering are principally to be used for the commercial launch of Bronchitol for cystic fibrosis in both Europe and the U.S. This placement means Pharmaxis can take an important additional step in building a profitable, international, pharmaceutical business. We are very pleased with the support from the participating institutions and look forward to bringing Bronchitol to the world.” said Pharmaxis Chief Executive Officer Dr Alan Robertson.

#ends#

SOURCE: Pharmaxis Ltd, Sydney, Australia
CONTACT: Alan Robertson — Chief Executive Officer
Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

RELEASED THROUGH:
Australia:
Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

United States:
Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com

Page 1 of 2

Forward-Looking Statements
The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the “Risk Factors and Other Uncertainties” section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

Page 2 of 2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Pharmaxis Ltd (Registrant)
Date: May 14, 2009	By:	/s/ David McGarvey
Date: June 4, 2009	By:	/s/ David McGarvey
		Name:	David McGarvey
		Title:	Chief Financial Officer

Filing Compare · Pharmaxis Ltd.